Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Transgene SA (GB:0OCQ)
LSE:0OCQ
Transgene (0OCQ) Share Price & Analysis
2 Followers
0OCQ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.05 - €2.30
Previous Close€1.28
Volume100.00
Average Volume (3M)125.00
Market Cap
€121.80M
Enterprise Value€97.42M
Total Cash (Recent Filing)€26.83M
Total Debt (Recent Filing)€2.45M
Price to Earnings (P/E)-5.7
Beta0.85
Next Earnings
May 14, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares OutstandingN/A
10 Day Avg. Volume6,831
30 Day Avg. Volume125
Standard Deviation0.10
R-Squared0.05
Alpha0.00322
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
0OCQ FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest share price was €1.04 and its highest was €2.29 in the past 12 months.
What is Transgene SA’s market cap?
Currently, no data Available
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is May 14, 2024 which is in 15 days.
How were Transgene SA’s earnings last quarter?
Transgene SA released its earnings results on Mar 27, 2024. The company reported -€0.064 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.064.
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 100,852,745 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Transgene SA reported an EPS of -€0.064 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in GB:0OCQ
---
Transgene Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-83.54%
Trailing 12-Months
Asset Growth
-31.94%
Trailing 12-Months
Company Description
Transgene SA
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. The firm is based in Strasbourg, France has additional operations in Lyon as well as satellite offices in China and United States.
---
Technical Analysis
---